Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Amazon Explores AI Content Marketplace With Media Publishers 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
NEW YORK, Jan. 29, 2018 -- On January 19, 2018, Safirstein Metcalf LLP and HGT Law commenced a shareholder “opt-out” lawsuit (“Lawsuit”) on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE:VRX) and its senior officers for violations of federal securities laws.
Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant (“Class Action”). The Investors have opted out of the Class Action to directly pursue their own claims. To date, this Lawsuit is the only opt-out action that has been filed on behalf of retail investors.
A copy of the complaint filed by Safirstein Metcalf LLP and HGT Law on behalf of the Investors can be found at www.valeantshareholderlitigation.com
If you purchased Valeant common stock during the Class Period and suffered losses of more than $200,000, then you may wish to consider opting out of the existing class action. If you would like to learn about the options available to you, please call 1-800-221-0015, email [email protected] or visit www.valeantshareholderlitigation.com
The class action is brought on behalf of purchasers of Valeant equity securities and senior notes between January 4, 2013 and March 15, 2016 (the “Class Period”).
| Company: | Valeant Pharmaceuticals International, Inc. |
| Exchange: | NYSE |
| Ticker: | VRX |
| Class Period: | 01/04/2013 – 03/15/2016 |
About Safirstein Metcalf LLP and HGT Law
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
HGT Law is a boutique commercial litigation firm based in New York. The firm focuses on representing investors in securities litigation and corporate governance/derivative litigation.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY 10001
1-800-221-0015
